Iovance Biotherapeutics, Inc. (LON:0JDK)
2.259
-0.022 (-0.96%)
At close: Dec 12, 2025
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $67.46M USD in the quarter ending September 30, 2025, with 15.20% growth. This brings the company's revenue in the last twelve months to $250.43M, up 175.62% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$250.43M
Revenue Growth
+175.62%
P/S Ratio
3.51
Revenue / Employee
$298.84K
Employees
838
Market Cap
653.88M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Iovance Biotherapeutics News
- 6 days ago - 2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
- 16 days ago - Iovance (IOVA) Q3 2025 Earnings Call Transcript - The Motley Fool
- 19 days ago - Iovance Biotherapeutics: Several Positives, But Competition Still Threatens - Seeking Alpha
- 22 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode - Seeking Alpha
- 4 weeks ago - Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - The Motley Fool
- 5 weeks ago - 2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - The Motley Fool
- 5 weeks ago - Chardan Capital Lowers Price Target for IOVA, Maintains Buy Rating | IOVA Stock News - GuruFocus